| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/02/2003 | EP1270044A2 Wound healing biomarkers |
| 01/02/2003 | EP1270011A1 Drugs for ameliorating impaired glucose tolerance |
| 01/02/2003 | EP1270004A1 Diuretics containing gamma-tocotrienol |
| 01/02/2003 | EP1270000A2 Benzoic acid substituted benzopyrans for the treatment of atherosclerosis |
| 01/02/2003 | EP1269196A1 Method of screening for inhibitors of osteopontin |
| 01/02/2003 | EP1268861A2 Diagnosis of diseases associated with dna transcription |
| 01/02/2003 | EP1268857A2 Diagnosis of diseases associated with gene regulation |
| 01/02/2003 | EP1268820A2 Estrogen-regulated myo-inositol phosphate synthase: compositions and methods of use |
| 01/02/2003 | EP1268816A2 Calcium-binding regulatory subunit |
| 01/02/2003 | EP1268802A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 01/02/2003 | EP1268799A2 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability |
| 01/02/2003 | EP1268798A2 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 01/02/2003 | EP1268792A2 Wnt-7b-like polypeptides and nucleic acids encoding same |
| 01/02/2003 | EP1268785A2 Gtp-binding protein gamma-12 subunit |
| 01/02/2003 | EP1268783A2 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 01/02/2003 | EP1268781A2 G12l, a gene associated with the thermal response |
| 01/02/2003 | EP1268771A1 Human gata-5 transcription factor |
| 01/02/2003 | EP1268760A1 Recombinant proteins containing shiga-like toxin and vascular endothelial growth factor fragments |
| 01/02/2003 | EP1268558A1 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 01/02/2003 | EP1268554A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 01/02/2003 | EP1268549A2 Method of identifying inhibitors of tie-2 |
| 01/02/2003 | EP1268544A2 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 01/02/2003 | EP1268543A2 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 01/02/2003 | EP1268507A1 Antisense modulation of e2f transcription factor 1 expression |
| 01/02/2003 | EP1268503A1 O-glucosylated benzamide sglt2 inhibitors and method |
| 01/02/2003 | EP1268502A1 O-aryl glucoside sglt2 inhibitors and method |
| 01/02/2003 | EP1268498A1 Cardioprotective phosphonates and malonates |
| 01/02/2003 | EP1268495A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268494A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268489A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 01/02/2003 | EP1268487A1 Tricyclic protein kinase inhibitors |
| 01/02/2003 | EP1268481A2 Kinase inhibitors as therapeutic agents |
| 01/02/2003 | EP1268480A1 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors |
| 01/02/2003 | EP1268476A1 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
| 01/02/2003 | EP1268474A2 Substituted 1,3-thiazole compounds, their production and use |
| 01/02/2003 | EP1268471A1 N-heterocyclic derivatives as nos inhibitors |
| 01/02/2003 | EP1268465A1 Triarylimidazole derivatives as cytokine inhibitors |
| 01/02/2003 | EP1268463A2 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade |
| 01/02/2003 | EP1268455A2 Piperazine derivatives |
| 01/02/2003 | EP1268453A1 Estrogen agonist/antagonist metabolites |
| 01/02/2003 | EP1268448A1 Bicyclic amine derivatives as inhibitors of class 1 receptor tyrosine kinases |
| 01/02/2003 | EP1268445A1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |
| 01/02/2003 | EP1268444A1 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrmidines as antineoplastic agents |
| 01/02/2003 | EP1268437A1 Inhibitors of protein kinases |
| 01/02/2003 | EP1268435A1 4,5-dihydro-1h-pyrazole derivatives having cb 1-antagonistic activity |
| 01/02/2003 | EP1268431A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| 01/02/2003 | EP1268429A1 Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same |
| 01/02/2003 | EP1268428A2 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade |
| 01/02/2003 | EP1268427A1 Aminopyridines and their use as anticonvulsants and sodium channel blockers |
| 01/02/2003 | EP1268425A2 Carbamate caspase inhibitors and uses thereof |
| 01/02/2003 | EP1268419A1 Pyrrolidine derivatives useful as bax inhibitors |
| 01/02/2003 | EP1268418A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors |
| 01/02/2003 | EP1268413A2 Substituted biphenyl derivatives |
| 01/02/2003 | EP1268407A1 Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
| 01/02/2003 | EP1268404A1 Malonamic acids and derivatives thereof as thyroid receptor ligands |
| 01/02/2003 | EP1268398A2 Novel method for synthesis of n- (s)-1-carboxybutyl]-(s)-alanine esters and use in synthesis of perindopril |
| 01/02/2003 | EP1268389A2 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
| 01/02/2003 | EP1268387A2 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators |
| 01/02/2003 | EP1268305A1 Infusion packet with useful and decorative elements, support member, delivery system and method |
| 01/02/2003 | EP1268096A1 Extrusion die |
| 01/02/2003 | EP1267954A1 Medical devices suitable for gene therapy regimens |
| 01/02/2003 | EP1267935A2 Novel treatment for eye disease |
| 01/02/2003 | EP1267926A2 Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2 |
| 01/02/2003 | EP1267917A1 Angiogenic onchocerca volvulus proteins and uses thereof |
| 01/02/2003 | EP1267915A2 Methods of treating diseases with activated protein c |
| 01/02/2003 | EP1267914A1 Use of lyosomal acid lipase for treating atherosclerosis and related diseases |
| 01/02/2003 | EP1267910A2 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
| 01/02/2003 | EP1267908A1 Vaccine for the treatment of atherosclerosis |
| 01/02/2003 | EP1267905A2 Composition for the treatment of heart failure |
| 01/02/2003 | EP1267901A1 Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress |
| 01/02/2003 | EP1267898A2 Bile acid containing prodrugs with enhanced bioavailability |
| 01/02/2003 | EP1267897A1 Treatment of congestive heart failure by pretreated autologous blood |
| 01/02/2003 | EP1267896A1 Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death |
| 01/02/2003 | EP1267888A1 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification |
| 01/02/2003 | EP1267882A2 Apoptosis inhibitor with prostaglandin structure |
| 01/02/2003 | EP1267878A2 Compounds with 5-ht activity useful for controlling visual field loss |
| 01/02/2003 | EP1267876A1 Thrombin inhibitors |
| 01/02/2003 | EP1267875A1 Sigma receptor ligands and their medical uses |
| 01/02/2003 | EP1267874A2 Therapeutic uses of ppar mediators |
| 01/02/2003 | EP1267865A2 Amiodarone-containing parenteral solution |
| 01/02/2003 | EP1267855A2 Vasopeptidase inhibitors to treat isolated systolic hypertension |
| 01/02/2003 | EP1267852A2 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
| 01/02/2003 | EP1267851A2 Method and compositions for preventing hormone induced adverse effects |
| 01/02/2003 | EP1267841A1 Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine |
| 01/02/2003 | EP1267839A2 Microspheres for active embolization |
| 01/02/2003 | EP1267837A1 Matrices containing nitric oxide donors and reducing agents and their use |
| 01/02/2003 | EP1267828A2 Pharmaceutical preparations |
| 01/02/2003 | EP1030831A4 Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides |
| 01/02/2003 | EP1019370B1 Ace-inhibitor nitric salts |
| 01/02/2003 | EP0980382B1 Estrogenic 19-norandrost-17-one derivatives with an aromatic b-ring |
| 01/02/2003 | EP0928195B1 Compositions for use in embolizing blood vessels |
| 01/02/2003 | EP0925286B1 Substituted pyrimidine derivatives and their pharmaceutical use |
| 01/02/2003 | EP0915859B1 Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
| 01/02/2003 | EP0883401B1 At1 receptor antagonist for the stimulation of apoptosis |
| 01/02/2003 | EP0863754B1 Hydrolysis-optimized lipid emulsions and use thereof |
| 01/02/2003 | EP0806960B1 Extracts of shark cartilage, process of production and uses thereof |
| 01/02/2003 | EP0804431B9 GLYCOPROTEIN IIb/IIIa ANTAGONISTS |
| 01/02/2003 | EP0771216B9 Methods and compositions for the specific coagulation of tumoral vasculature |
| 01/02/2003 | CA2414726A1 Bicyclic lactams and sulfonamides with 5-ht1a-affinity and use thereof for preventing and treating cerebral ischaemia |
| 01/01/2003 | CN1388126A 吡咯并三嗪和嘧啶化合物 Pyrrolo-triazine and pyrimidine compounds |